Search Results
Dec 20, 2025, 13:47 ET ETHGas 推出以太坊區塊空間期貨市場，獲 8 億美元承諾資金及 1,200 萬美元種子輪融資，由 Polychain Capital 領投
Polychain 領投，知名投資者包括 Stake Capital、BlueYard Capital、Lafayette Macro Advisors、SIG DT 及 Amber Group，同時參與的還有以太坊驗證者、區塊建設者及中繼服務提供者。這些合作夥伴共同承諾提供 8 億美元的初始資金，用以支持 ETHGas 的市場平台與產品開發。ETHGas 簡介EthGas 是以太坊 (Ethereum) 區塊空間期貨市場。ETHGas
More news about: ETHGas
Dec 20, 2025, 13:43 ET ETHGas estrena el mercado de futuros de blockspace de Ethereum con 800 millones de dólares en compromisos y una ronda de financiación inicial de 12 millones de dólares liderada por Polychain Capital
Polychain y en la que participan inversores destacados como Stake Capital, BlueYard Capital, Lafayette Macro Advisors, SIG DT y Amber Group, así como validadores, creadores de bloques y retransmisores de Ethereum. En conjunto, estas partes han aportado un compromiso inicial
More news about: ETHGas
Dec 19, 2025, 22:00 ET ETHGas debuteert Ethereums Blockspace Futures Market met $800 miljoen aan verbintenissen en $12 miljoen seed-ronde onder leiding van Polychain Capital
Polychain en met opmerkelijke investeerders zoals Stake Capital, BlueYard Capital, Lafayette Macro Advisors, SIG DT en Amber Group, evenals Ethereum-validatoren, blockbouwers en relays. Samen hebben deze partijen een initiële bijdrage van US $ 800 miljoen geleverd
More news about: ETHGas
Dec 19, 2025, 18:31 ET ETHGas startet den Ethereum-Blockspace-Terminmarkt mit Zusagen in Höhe von 800 Millionen US-Dollar und einer Seed-Runde über 12 Millionen US-Dollar unter Führung von Polychain Capital
Polychain erfolgt und an der sich namhafte Investoren wie Stake Capital, BlueYard Capital, Lafayette Macro Advisors, SIG DT und Amber Group sowie Ethereum-Validierer, Block-Builder und Relays beteiligen. Zusammen haben diese Parteien zunächst 800 Millionen US-Dollar an Zusagen
More news about: ETHGas
Dec 19, 2025, 18:27 ET ETHGas lance le marché à terme de la chaîne de blocage d'Ethereum avec 800 millions de dollars d'engagements et un tour de table de 12 millions de dollars mené par Polychain Capital.
Polychain et auquel participent des investisseurs de renom tels que Stake Capital, BlueYard Capital, Lafayette Macro Advisors, SIG DT et Amber Group, ainsi que des validateurs, des constructeurs de blocs et des relais Ethereum. Ensemble, ces parties ont pris des engagements d'un montant
More news about: ETHGas
Dec 19, 2025, 08:02 ET ETHGas Debuts Ethereum's Blockspace Futures Market with $800m of Commitments and $12m Seed Round Led by Polychain Capital
Polychain and featuring notable investors such as Stake Capital, BlueYard Capital, Lafayette Macro Advisors, SIG DT and Amber Group, as well as Ethereum validators, block builders and relays. Together, these parties have contributed an initial US$800m
More news about: ETHGas
Dec 16, 2025, 09:15 ET SILICONE IGNITION BOOTS MANY SHAPES, STYLES & COLORS OFFERED
Boots include the 115-degree design which is available in four heat ranges up to 600oF. For high performance GM V8 Engines, styles include DT975-SS, FE-1, CB167-BS, and AB28-BS with the SP98-SS. The firm also makes a full range of standard and custom air-operated booters.ETCO Silicone Ignition
More news about: ETCO Incorporated
Dec 10, 2025, 08:30 ET Christmas Adventure Awaits: Ausom Ignites the Holidays with High-Performance E-Scooters
frame (287 lbs load capacity) ensure stability on any path.Ausom DT2 Pro: Performance ChampionFor peak performance enthusiasts, the DT2 Pro stands alone. Advanced hydraulic disc brakes with E-ABS deliver unmatched
More news about: Ausom Electric Scooter
Dec 04, 2025, 08:37 ET Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim
domain with diphtheria toxin (DT) fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the DT fragment is cleaved and the free DT fragments inhibit protein synthesis,
More news about: Citius Oncology, Inc.
Dec 01, 2025, 12:00 ET Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)
domain with diphtheria toxin (DT) fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the DT fragment is cleaved and the free DT fragments inhibit protein synthesis,
More news about: Citius Oncology, Inc.
Nov 25, 2025, 08:00 ET Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting
domain with diphtheria toxin (DT) fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the DT fragment is cleaved and the free DT fragments inhibit protein synthesis,
More news about: Citius Oncology, Inc.
Nov 21, 2025, 08:37 ET Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration
domain with diphtheria toxin (DT) fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the DT fragment is cleaved and the free DT fragments inhibit protein synthesis,
More news about: Citius Oncology, Inc.
Nov 19, 2025, 11:08 ET Dialectic Therapeutics Announces Dosing of First Patient in Platinum-Resistant Ovarian Cancer (PROC)
RP2D showed that DT2216 degraded the intended BCL-XL target protein in all patients within this dosing cohort, demonstrating powerful and precise target engagement. In collaboration with Dr. Kristopher Sarosiek at Harvard School of Public Health, the effects of DT2216 were evaluated
More news about: Dialectic Therapeutics, Inc.
Nov 18, 2025, 08:00 ET Grand Island Central Schools Expands ZeroEyes AI Gun Detection and Intelligent Situational Awareness Solution
Department of Homeland Security (DHS) as a promising anti-terrorism technology and was the first video analytics technology to receive full SAFETY Act DT&E Designation. Founded by Navy SEALs and elite technologists, ZeroEyes dispatches accurate and real-time actionable intelligence
More news about: ZeroEyes
Nov 14, 2025, 13:30 ET Continental Towers Majority Shareholders Will Pursue Counterclaims Following Conclusion of Disputed Arbitration Process
Nov. 14, 2025 /PRNewswire/ -- Terra Towers, the majority shareholder of Continental Towers along with TBS Management and DT Holdings, today issued the following statement regarding the conclusion of arbitration proceedings marked by irregularities and controversies.
More news about: Terra Towers
Nov 13, 2025, 07:42 ET Domain Therapeutics Appoints Boston-Based Pharma Leader Jean-Marie Cuillerot, M.D., as Chief Medical Officer
seasoned leadership, he will guide the development of DT-7012 while helping shape the strategic trajectory of Domain's other proprietary and highly differentiated drug candidates, including DT-9081, an EP4 receptor antagonist for solid tumors, and DT-9046, a first-in-class biased negative allosteric modulator
More news about: Domain Therapeutics
Oct 28, 2025, 04:30 ET Domain Therapeutics Doses First Patients in Phase I/II Trial of DT-7012 Targeting CCR8 in Solid Tumors
pharmaceutical companies. DT-7012 stands out with its unique and differentiating properties, offering unprecedented selectivity in depleting intratumoral Tregs while simultaneously improving overall immune system function. These features are critical for effective cancer immunotherapy, positioning DT-7012 as a promising
More news about: Domain Therapeutics
Oct 27, 2025, 07:30 ET TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years
D'Haens GR, Rubin DT, et al. Efficacy and Safety of Guselkumab Through Week 96 After Intravenous or Subcutaneous Induction in Participants With Crohn's Disease: Phase 3 Long-term
More news about: Johnson & Johnson
Oct 23, 2025, 09:18 ET ZTE veranstaltet ZTE Broadband User Congress 2025 in Mexiko-Stadt unter dem Motto „AI Boosting Broadband Benefits"
Der diesjährige Kongress stand unter dem Motto „AI Boosting Broadband Benefits" (dt. „KI steigert die Vorteile von Breitband") und brachte über 400 weltweit führende Vertreter der IKT-Branche, Top-Telekommunikationsbetreiber, Pioniere
More news about: ZTE Corporation
Oct 20, 2025, 08:37 ET Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch
cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the DT fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death. Denileukin diftitox-cxdl demonstrated the ability to deplete immunosuppressive
More news about: Citius Oncology, Inc.
Oct 16, 2025, 08:47 ET Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™
cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the DT fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death. Denileukin diftitox-cxdl demonstrated the ability to deplete immunosuppressive
More news about: Citius Oncology, Inc.
Oct 07, 2025, 08:47 ET Citius Oncology Establishes International Access to LYMPHIR™ via Named Patient Programs in Southern Europe
binding domain with diphtheria toxin (DT) fragments. The agent specifically binds to IL-2 receptors on the cell surface of tumor cells and immunosuppressive regulatory T-cells (T-regs) and is internalized. After uptake into the cell, the DT fragment is cleaved and the free DT fragments inhibit protein synthesis,
More news about: Citius Oncology, Inc.
Oct 06, 2025, 13:28 ET Havis Expands Rugged Mobility Solutions with New Docking Station for DT Research's DT323 Series Tablets
Havis. "By working closely with DT Research, we are proud to deliver rugged docking solutions that strengthen productivity, safety, and security across industries." Explore the new Havis docking station for the DT Research DT323 at
More news about: Havis, Inc.
Oct 02, 2025, 08:00 ET Kanawha County Schools First in West Virginia to Deploy ZeroEyes AI Gun Detection and Situational Awareness Technology
Department of Homeland Security (DHS) as a promising anti-terrorism technology and was the first video analytics technology to receive full SAFETY Act DT&E Designation. Founded by Navy SEALs and elite technologists, ZeroEyes dispatches accurate and real-time actionable intelligence
More news about: ZeroEyes
Sep 30, 2025, 11:58 ET Experience the Flavors of Kissimmee with the New Latin Culinary Trail
more than 55% of Osceola County identifying as Hispanic or Latino, our community's culture and cuisine are central to the Kissimmee experience," said DT Minich, President and CEO of Experience Kissimmee. "Partnering with Atlas Obscura allows us to shine a spotlight on these traditions, showcasing hidden
More news about: Experience Kissimmee